Form 4: Ventyx Biosciences Director Acquires 130,000 Shares

Sheila Gujrathi, a director at Ventyx Biosciences, purchased 130,000 shares of common stock at an average price of $2.3121 per share.

Summary

• Sheila Gujrathi, a director of Ventyx Biosciences, acquired 130,000 shares of the company's common stock on December 23, 2024.
• The shares were purchased at a weighted average price of $2.3121, with individual prices ranging from $2.275 to $2.38.
• The transaction was made indirectly through the Jordan Yechiel Cohen and Sheila Kumari Gujrathi AB Living Trust, where Ms. Gujrathi serves as a co-trustee.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, as it reports a standard insider transaction. The purchase by a director could be seen as a slightly positive signal, but it's not a major event.

Positives

• A director's purchase of shares can be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The purchase of shares by a director is a common occurrence and is not unusual in the biotech industry.

Stakeholder Impact

• The purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Ventyx Biosciences, insider trading, share purchase, director, common stock, Sheila Gujrathi